APA (7th ed.) Citation

Vande Casteele, N., Abreu, M. T., Flier, S., Papamichael, K., Rieder, F., Silverberg, M. S., . . . Cheifetz, A. S. (2022). Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor. Clinical gastroenterology and hepatology, 20(2), 465-467.e2. https://doi.org/10.1016/j.cgh.2021.01.006

Chicago Style (17th ed.) Citation

Vande Casteele, Niels, et al. "Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor." Clinical Gastroenterology and Hepatology 20, no. 2 (2022): 465-467.e2. https://doi.org/10.1016/j.cgh.2021.01.006.

MLA (9th ed.) Citation

Vande Casteele, Niels, et al. "Patients With Low Drug Levels or Antibodies to a Prior Anti–Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti–Tumor Necrosis Factor." Clinical Gastroenterology and Hepatology, vol. 20, no. 2, 2022, pp. 465-467.e2, https://doi.org/10.1016/j.cgh.2021.01.006.